- Published on: February 5, 2024
- 13:51
Beijing, Feb 5 (Prensa Latina) China on Monday approved the registration of Nimotuzumab, a Cuban humanized monoclonal antibody to treat head and neck cancer, a new milestone in biotechnological cooperation between the two countries.
